Krystal Biotech KRYS
$308.89 −$6.93 (-2.19%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $308.85 -0.01%
Open$313.38
Prev close$315.82
Day range$308.22 – $321.27
Volume286.7K
Market cap$9.15B
P/E (TTM)42.0
Dividend yield–
KRYS Stock News
Headlines matching Krystal Biotech or the KRYS ticker, most recent first.
- Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock
- Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441 Positive
- BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400 Positive
- Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $386 Positive
- BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Cuts Target Price to $392 Negative
- H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $361
- TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $403
- William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
- RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400
- Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock
- Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating
- BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396 Positive
- Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474 Positive
- TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403 Positive
- H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $361 Positive
No comments yet — be the first to weigh in on KRYS.
Sign in to join the discussion.